Papers/PMID:35447899
Fucoxanthin Attenuates Free Fatty Acid-Induced Nonalcoholic Fatty Liver Disease by Regulating Lipid Metabolism/Oxidative Stress/Inflammation via the AMPK/Nrf2/TLR4 Signaling Pathway.
Marine drugs2022The record
1 finding · 1 compound · 1 endpoint
What it reported
How to read these marksWhat moved
1 finding
fucoxanthin — inhibits TLR4
PreliminaryGrade D, Preliminary. Human evidence with major recorded weaknesses, or non-human, uncontrolled or unverified evidence.Finding“The expression of TLR4 and its downstream proteins myeloid differentiation factor 88 (MyD88), p-IκBα, and p-NF-κBp65 was significantly upregulated in the FFA group, and was significantly inhibited by treatment with fucoxanthin.”
Quoted verbatim from Fucoxanthin Attenuates Free Fatty Acid-Induced Nonalcoholic Fatty Liver Disease by Regulating Lipid Metabolism/Oxidative Stress/Inflammation via the AMPK/Nrf2/TLR4 Signaling Pathway.. - Study
- in vitro · not in humans
- Population
- Human Chang liver cell line, FFA-induced NAFLD cell model, fucoxanthin group
Fucoxanthin Attenuates Free Fatty Acid-Induced Nonalcoholic Fatty Liver Disease by Regulating Lipid Metabolism/Oxidative Stress/Inflammation via the AMPK/Nrf2/TLR4 Signaling Pathway.2022PMID:35447899Permalink